Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma
Davis, Meredith R.
Krajewksi, Katherine M.
MetadataShow full item record
CitationMarmarelis, Melina E., Meredith R. Davis, Nilay S. Sethi, Katherine M. Krajewksi, Rana R. McKay, Toni K. Choueiri, and Patrick A. Ott. 2016. “Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma.” Journal for Immunotherapy of Cancer 4 (1): 26. doi:10.1186/s40425-016-0129-x. http://dx.doi.org/10.1186/s40425-016-0129-x.
AbstractBlockade of the immunological checkpoint programmed death 1 (PD-1) using monoclonal antibodies has shown robust anti-tumor activity across a broad range of solid and hematological malignancies including melanoma and renal cell carcinoma (RCC). Characteristic markers such as the presence of tumor infiltrating lymphocytes, PD-L1 status, and mutational load may be equally or even more important in predicting clinical benefit from PD-1 pathway blockade than tumor histology. This case of a patient with concurrent metastatic melanoma and metastatic RCC, both of which were controlled for more than a year after a single dose of the anti-PD-1 antibody pembrolizumab, illustrates the potential to simultaneously treat distinct immunogenic tumors with anti-PD-1 agents.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:26860040
- HMS Scholarly Articles